ImaginAb has collaborated with
AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour
imaging and monitoring inside the cells.
ImaginAb is an emerging imaging
company focused on immune-oncology. The technology also helps in targeting and
visualizing CD8+ T cells, which are activated by the immunotherapy and induce
cell death.
Under the terms of the agreement, the collaborators will advance the current ImaginAb-sponsored clinical trials that aim to study the utility and value of CD8 ImmunoPet in the immune-oncology pipeline.
In return, collaborators will
gain access to data of clinical and imaging data that will help them analyse the
post...